&nbsp;

Poster.zip

Nov 2024

Regimen

PEMB+TRAS(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Drugs Used:

pembrolizumab,

trastuzumab

Quick Link(s):

Regimen Monograph

Dec 2024

Document

Safe-to-Switch.png

Jan 2025

Plan pour la lutte contre le cancer en Ontario 6 (2024 à 2028)

Regimen

PEME+AMIV(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

pemetrexed,

amivantamab (Unfunded)

Quick Link(s):

Regimen Monograph

Jan 2025

Document

Systemic-Treatment-Implementation-Plan-2024-2028-EN.pdf

Jan 2025

Document

Systemic-Treatment-Implementation-Plan-2024-2028-FR

Jan 2025

Document

Standardized-Adnexal-Masses-US-Reporting-Explanatory-Notes.pdf

Jan 2025

Regimen

PEMB(MNT)

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

PIRT

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

pirtobrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Feb 2025

Drug

selpercatinib

Other Name(s): Retevmo™

Quick Link(s): Drug Monograph, Patient Info Sheet

May 2025

Document